Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2012
11/22/2012WO2012158658A1 Fused bicyclic kinase inhibitors
11/22/2012WO2012158413A2 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
11/22/2012WO2012158358A1 Treatment and prognosis of cancer
11/22/2012WO2012157744A1 1-THIOXO-1,2,3,4-TETRAHYDRO-β-CARBOLINE DERIVATIVE AND ANTI-CANCER AGENT COMPRISING SAME
11/22/2012WO2012157737A1 Immunity inducing agent
11/22/2012WO2012157736A1 Immunity induction agent
11/22/2012WO2012157721A1 Liposome containing pyrroloquinoline quinone and sugar
11/22/2012WO2012157672A1 Method for predicting effectiveness of angiogenesis inhibitor
11/22/2012WO2012157647A1 Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
11/22/2012WO2012157589A1 Cell adhesion inhibitor, cell proliferation inhibitor, and method and kit for testing cancer
11/22/2012WO2012157408A1 Cytotoxic t cell inducer
11/22/2012WO2012157389A1 Low-molecular-weight compound capable of regulating rac activation induced by dock-a subfamily molecule, and use thereof
11/22/2012WO2012157239A1 Chodl as tumor marker and therapeutic target for cancer
11/22/2012WO2012157128A1 Metal complex and pharmaceutical composition containing same
11/22/2012WO2012156975A1 COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
11/22/2012WO2012156877A1 Epicutaneous. skin cancer, basal, squamous, melanoma, collagen, procolla1, mmp1
11/22/2012WO2012156756A2 New compounds
11/22/2012WO2012156532A1 Anti-human-her3 antibodies and uses thereof
11/22/2012WO2012156511A1 Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
11/22/2012WO2012156463A1 Novel cancer therapies and methods
11/22/2012WO2012156380A1 Method for treatment of advanced solid tumors
11/22/2012WO2012156367A1 Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
11/22/2012WO2012156289A1 Pharmaceutical compositions comprising neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
11/22/2012WO2012156283A1 Method for treatment of solid malignancies including advanced or metastatic solid malignancies
11/22/2012WO2012155824A1 Ancomycin and its derivatives, preparation methods and uses thereof
11/22/2012WO2012155806A1 4-aminoquinazoline derivatives and uses thereof
11/22/2012WO2012155559A1 Organic hybridized tetra-core platinum complex and preparation method thereof as well as the use thereof in manufacturing medicament for antitumor
11/22/2012WO2012155339A1 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
11/22/2012WO2012155328A1 Composition comprising endostatin and rnai molecules and the use thereof
11/22/2012WO2012139001A3 Kinase protein binding inhibitors
11/22/2012WO2012135149A9 Small molecule modulators of sirt1 activity activate p53 and suppress tumor growth
11/22/2012WO2012131656A3 Compounds for use as therapeutic agents affecting p53 expression and/or activity
11/22/2012WO2012131004A3 Antibodies directed against icos and uses thereof
11/22/2012WO2012129873A3 Method for preparing antitumor biological product
11/22/2012WO2012118915A3 Compositions and methods for treatment of tamoxifen resistant breast cancer
11/22/2012WO2012116196A3 Substituted lactosyl compounds and use thereof for cellular imaging and therapy
11/22/2012WO2012112956A3 Compounds and methods for targeting leukemic stem cells
11/22/2012WO2012106713A3 Targeted nanoparticle conjugates
11/22/2012WO2012096718A3 Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
11/22/2012WO2012092288A3 Compositions and methods of using crystalline forms of wortmannin analogs
11/22/2012WO2012082752A3 Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
11/22/2012WO2012072715A3 Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
11/22/2012WO2012068169A3 Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments
11/22/2012WO2012065057A3 Phosphatidylinositol 3-kinase inhibitors and methods of their use
11/22/2012WO2012037008A3 Therapy for mll-rearranged leukemia
11/22/2012US20120297493 Gene Therapy Using Transposon-Based Vectors
11/22/2012US20120296403 Methods and compounds for muscle growth
11/22/2012US20120296088 Synthesis of udp-glucose: n-acylsphingosine glucosyl transferase inhibitors
11/22/2012US20120296072 N-terminally chemically modified protein compositions and methods
11/22/2012US20120295990 Insulin Receptor Substrate 1 (IRS1) Protein SRM/MRM Assay
11/22/2012US20120295988 Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers
11/22/2012US20120295980 Compounds and methods for delivery of prostacyclin analogs
11/22/2012US20120295971 Therapeutic compositions
11/22/2012US20120295970 Therapeutic compositions
11/22/2012US20120295968 Pharmaceutical Composition Comprising Cannabinoids
11/22/2012US20120295965 Fused thiophenes as dual inhibitors of egfr/vegfr and their use in the treatment of cancer
11/22/2012US20120295962 Targeting micrornas for the treatment of liver cancer
11/22/2012US20120295961 Modulation of hepatitis b virus (hbv) expression
11/22/2012US20120295959 Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
11/22/2012US20120295955 Rna antagonist compounds for the modulation of her3
11/22/2012US20120295954 Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
11/22/2012US20120295953 Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
11/22/2012US20120295952 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
11/22/2012US20120295951 Genetic changes in atm and atr/chek1 as prognostic indicators in cancer
11/22/2012US20120295949 Microrna-based methods and compositions for the diagnosis, prognosis and treatment of tumor involving chromosomal rearrangements
11/22/2012US20120295948 Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
11/22/2012US20120295944 Treatment of hyperproliferative disorders with diarylhydantoin compounds
11/22/2012US20120295937 Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
11/22/2012US20120295932 Method for the treatment of cancer
11/22/2012US20120295929 Compositions and methods for treating and preventing dermatoses
11/22/2012US20120295928 Methods for detecting and reducing impurities of lapatinib and salts thereof
11/22/2012US20120295927 Methods of using selective chemotherapeutic agents for targeting tumor cells
11/22/2012US20120295926 Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same
11/22/2012US20120295918 Cancer treatment method
11/22/2012US20120295917 Imatinib dichloroacetate and anti-cancer agent comprising the same
11/22/2012US20120295915 Azabenzimidazoles as fatty acid synthase inhibitors
11/22/2012US20120295913 Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
11/22/2012US20120295909 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
11/22/2012US20120295908 Pyrimidinyl pyridazinone derivatives
11/22/2012US20120295906 Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furane-derivatives as kinase inhibitors
11/22/2012US20120295902 Hetaryl-[1,8]naphthyridine derivatives
11/22/2012US20120295900 1,3-oxazines as bace 1 and/or bace2 inhibitors
11/22/2012US20120295897 Spiro-oxindole compounds and their uses as therapeutic agents
11/22/2012US20120295896 Oxadiazole inhibitors of leukotriene production
11/22/2012US20120295890 Glycosaminoglycan inhibitors
11/22/2012US20120295889 3-Arylamino Pyridine Derivatives
11/22/2012US20120295887 Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof
11/22/2012US20120295883 Compounds
11/22/2012US20120295878 Method for the treatment of cancer
11/22/2012US20120295877 Therapeutic Compounds
11/22/2012US20120295871 Heparin-based compositions and methods for the inhibition of metastasis
11/22/2012US20120295864 Method for treating acute myeloid leukemia
11/22/2012US20120295861 Combination Therapy With Organic Arsenicals
11/22/2012US20120295856 Fredericamycin derivatives
11/22/2012US20120295848 Sustained-release composition and process for producing the same
11/22/2012US20120295835 Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth
11/22/2012US20120295350 Prospective Identification and Characterization of Breast Cancer Stem Cells
11/22/2012US20120294957 Treatment of lung cancer
11/22/2012US20120294956 Inhibition of dynamin related protein 1 to promote cell death
11/22/2012US20120294955 Use of arsenic for cancer therapy protection
1 ... 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 ... 2211